PYC Therapeutics Limited (AU:PYC) has released an update.
PYC Therapeutics Limited has reported positive safety data from clinical trials of their first drug candidate, VP-001, aimed at treating the genetic eye disease Retinitis Pigmentosa type 11 (RP11). Four patient cohorts have been safely dosed without serious adverse events, with the highest dose showing no adverse effects, paving the way for a Multiple Ascending Dose study. These results offer hope for RP11 patients, who currently lack treatment options, and could lead to a new drug application by 2025.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.
